A new class of selective estrogen receptor degraders has shown promise in ER+/HER-2- breast cancer; a recent phase 3 trial on elacestrant showed significant benefit in patients with ESR1 mutation versus standard of care and another phase 2 on camizestrant demonstrated superior PFS when compared to fulvestrant (55, 56). Here, ERBB2 is linked to breast carcinoma.